12:00 AM
 | 
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Panobacumab: Phase IIa data

Data from an open-label, European Phase IIa trial in 13 evaluable patients showed that panobacumab resulted in a 28-day mortality rate of 7% compared to 25.6% as predicted by the acute physiology and chronic...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >